Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
anti-VEGF therapy |
| gptkbp:approvalYear |
2023
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:S01XA60
|
| gptkbp:brand |
Izervay
|
| gptkbp:developedBy |
gptkb:Iveric_Bio
|
| https://www.w3.org/2000/01/rdf-schema#label |
avacincaptad pegol
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
RNA aptamer
|
| gptkbp:mechanismOfAction |
complement C5 inhibitor
|
| gptkbp:routeOfAdministration |
intravitreal injection
|
| gptkbp:target |
complement C5 protein
|
| gptkbp:usedFor |
gptkb:geographic_atrophy
age-related macular degeneration |
| gptkbp:bfsParent |
gptkb:Zimura
|
| gptkbp:bfsLayer |
7
|